US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Bright Minds Biosciences Inc
(CSE:
DRUG
)
72.53
+1.94 (+2.75%)
Delayed Quote
Updated: 1:07 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bright Minds Biosciences Inc
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
September 30, 2026
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
May 26, 2026
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
January 09, 2026
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
March 04, 2025
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
February 24, 2025
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
January 07, 2025
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
November 21, 2024
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
November 04, 2024
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
October 21, 2024
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
October 16, 2024
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
October 03, 2024
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
September 19, 2024
From
Bright Minds Biosciences
Via
GlobeNewswire
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
October 05, 2022
A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same transformational effects as a near-death experience (NDE). The...
Via
PressReach
Topics
Supply Chain
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
October 05, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking...
Via
FinancialNewsMedia
